The cornea in keratoconjunctivitis sicca.

Stephen C Pflugfelder, Michael E Stern
Author Information
  1. Stephen C Pflugfelder: Department of Ophthalmology, Baylor College of Medicine, Houston, TX, United States. Electronic address: stevenp@bcm.edu.
  2. Michael E Stern: Department of Ophthalmology, Baylor College of Medicine, Houston, TX, United States; ImmunEyez, Mission Viejo, CA, United States. Electronic address: michaelestern4@gmail.com.

Abstract

The lacrimal functional unit (LFU) regulates tear production, composition, distribution and clearance to maintain a stable protective tear layer that is essential for maintaining corneal epithelial health. Dysfunction of the LFU, commonly referred to as dry eye, leads to increased tear osmolarity and levels of inflammatory mediators in tears that cause ocular surface epithelial disease, termed keratoconjunctivitis sicca (KCS). Corneal changes in KCS include glycocalyx loss, barrier disruption, surface irregularity inflammatory cytokine/chemokine production, cornification and apoptosis. These can reduce visual function and the increased shear force on the corneal epithelium can stimulate nociceptors sensitized by inflammation causing irritation and pain that may precede frank clinical signs. Therapy of keratoconjunctivitis sicca should be tailored to improve tear stability, normalize tear composition, improve barrier function and minimize shear forces and damaging inflammation to improve corneal epithelial health.

Keywords

References

Exp Eye Res. 2018 Apr;169:91-98 [PMID: 29407221]
Arch Ophthalmol. 2002 Mar;120(3):330-7 [PMID: 11879137]
Jpn J Ophthalmol. 2011 Sep;55(5):451-459 [PMID: 21717178]
Am J Pathol. 2005 Jan;166(1):61-71 [PMID: 15632000]
Int J Mol Sci. 2020 Jun 18;21(12): [PMID: 32570730]
Am J Ophthalmol. 2017 Oct;182:90-98 [PMID: 28705660]
Curr Eye Res. 2015 Jul;40(7):657-67 [PMID: 25271595]
Sci Rep. 2020 Feb 19;10(1):2933 [PMID: 32076085]
Exp Eye Res. 2010 Mar;90(3):444-51 [PMID: 20036239]
PLoS One. 2014 Jun 26;9(6):e100393 [PMID: 24968021]
Mol Vis. 2014 Sep 12;20:1243-52 [PMID: 25352733]
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3318-26 [PMID: 20107168]
Ocul Surf. 2003 Oct;1(4):192-201 [PMID: 17075650]
Exp Eye Res. 2004 Mar;78(3):513-25 [PMID: 15106930]
Cornea. 1998 Jul;17(4):376-9 [PMID: 9676908]
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2544-57 [PMID: 10937565]
Mucosal Immunol. 2016 Jan;9(1):206-17 [PMID: 26129651]
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3203-9 [PMID: 19255163]
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2561-9 [PMID: 17525185]
Nat Med. 2010 Dec;16(12):1396-9 [PMID: 21076394]
Cornea. 2007 May;26(4):452-60 [PMID: 17457195]
J Cataract Refract Surg. 2012 Jul;38(7):1192-7 [PMID: 22727288]
Exp Eye Res. 2008 Jun;86(6):879-85 [PMID: 18436208]
Ocul Surf. 2014 Oct;12(4):252-66 [PMID: 25284771]
Prog Retin Eye Res. 2015 Mar;45:132-64 [PMID: 25479602]
Cornea. 2007 Dec;26(10):1195-9 [PMID: 18043175]
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2553-60 [PMID: 17525184]
Ocul Surf. 2015 Apr;13(2):103-9 [PMID: 25881994]
Cornea. 2010 Nov;29 Suppl 1:S62-7 [PMID: 20935545]
Eye (Lond). 2020 May;34(5):915-922 [PMID: 31576026]
PLoS One. 2015 May 29;10(5):e0126561 [PMID: 26024535]
Ocul Surf. 2018 Jul;16(3):368-376 [PMID: 29772277]
J Autoimmun. 2020 Nov;114:102500 [PMID: 32565048]
J Immunol. 2011 Oct 1;187(7):3653-62 [PMID: 21880984]
Invest Ophthalmol Vis Sci. 2013 Aug 01;54(8):5144-50 [PMID: 23833066]
Cornea. 2008 Jan;27(1):64-9 [PMID: 18245969]
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2847-56 [PMID: 16799024]
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5503-11 [PMID: 26284556]
Ocul Surf. 2020 Apr;18(2):199-205 [PMID: 32112874]
Am J Ophthalmol. 2011 Apr;151(4):682-690.e2 [PMID: 21269603]
Cornea. 1998 Nov;17(6):654-63 [PMID: 9820947]
Cornea. 2008 Sep;27(8):935-40 [PMID: 18724157]
Am J Ophthalmol. 2014 Jan;157(1):63-68.e2 [PMID: 24200234]
Clin Exp Immunol. 2016 May;184(2):248-56 [PMID: 26690299]
Invest Ophthalmol Vis Sci. 2014 Sep 04;55(9):6116-26 [PMID: 25190648]
Arch Ophthalmol. 1991 Mar;109(3):349-53 [PMID: 2003793]
Arch Ophthalmol. 2009 Jul;127(7):882-7 [PMID: 19597109]
Eye Contact Lens. 2008 Sep;34(5):281-6 [PMID: 18779668]
Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):456-61 [PMID: 20631241]
Prog Retin Eye Res. 1998 Oct;17(4):565-96 [PMID: 9777650]
Optom Vis Sci. 2019 Jun;96(6):387-396 [PMID: 31116166]
Nat Commun. 2015 May 11;6:6931 [PMID: 25959047]
Mucosal Immunol. 2014 Mar;7(2):417-27 [PMID: 24022789]
Prog Retin Eye Res. 2015 Jan;44:36-61 [PMID: 25461622]
Ocul Surf. 2014 Apr;12(2):87-99 [PMID: 24725321]
Optom Vis Sci. 2014 Dec;91(12):1446-54 [PMID: 25279779]
Allergy. 2009 May;64(5):710-7 [PMID: 19220217]
Ophthalmic Res. 2007;39(3):124-9 [PMID: 17374962]
Ophthalmology. 1999 May;106(5):939-43 [PMID: 10328393]
Exp Eye Res. 2006 Apr;82(4):588-96 [PMID: 16202406]
Cornea. 1998 Jan;17(1):38-56 [PMID: 9436879]
Curr Eye Res. 1988 May;7(5):483-6 [PMID: 3409715]
Cornea. 2007 Jun;26(5):579-84 [PMID: 17525655]
Am J Pathol. 2016 Jun;186(6):1547-58 [PMID: 27085137]
Exp Eye Res. 2004 Mar;78(3):409-16 [PMID: 15106920]
Cont Lens Anterior Eye. 2013 Aug;36(4):159-63 [PMID: 23499361]
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2181-2197 [PMID: 31108549]
Br J Ophthalmol. 2004 May;88(5):647-52 [PMID: 15090417]
J Rheumatol. 1996 Feb;23(2):313-20 [PMID: 8882038]
Ocul Surf. 2020 Apr;18(2):326-334 [PMID: 31953222]
Exp Eye Res. 2014 Aug;125:1-8 [PMID: 24836981]
Adv Colloid Interface Sci. 2014 Apr;206:250-64 [PMID: 23842140]
Eye (Lond). 2003 Nov;17(8):989-95 [PMID: 14631406]
Am J Ophthalmol. 2002 Feb;133(2):181-6 [PMID: 11812420]
Invest Ophthalmol Vis Sci. 2012 Aug 13;53(9):5443-50 [PMID: 22789923]
Pain. 1982 Oct;14(2):105-20 [PMID: 7177676]
Int Ophthalmol Clin. 2017 Spring;57(2):109-118 [PMID: 28282318]
Eye Contact Lens. 2005 Sep;31(5):186-93 [PMID: 16163009]
Invest Ophthalmol Vis Sci. 2007 May;48(5):2017-22 [PMID: 17460255]
Curr Eye Res. 2014 Mar;39(3):213-31 [PMID: 24215436]
Ophthalmology. 2003 Jun;110(6):1102-9 [PMID: 12799233]
Mucosal Immunol. 2009 May;2(3):243-53 [PMID: 19242409]
J Autoimmun. 2017 Jun;80:65-76 [PMID: 28238526]
Int J Mol Sci. 2018 Nov 30;19(12): [PMID: 30513621]
Cont Lens Anterior Eye. 2014 Jun;37(3):213-23 [PMID: 24332360]
Ophthalmology. 2020 Jan;127(1):14-26 [PMID: 31585826]
Exp Eye Res. 2012 Jan;94(1):150-6 [PMID: 22166618]
Ocul Surf. 2017 Jul;15(3):404-437 [PMID: 28736339]
Am J Ophthalmol. 2015 Jul;160(1):135-42.e1 [PMID: 25868759]
Invest Ophthalmol Vis Sci. 2011 Jun 01;52(6):3492-9 [PMID: 21421863]
Ophthalmologe. 2009 Nov;106(11):980-7 [PMID: 19941141]
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):124-9 [PMID: 12506064]
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES157-DES162 [PMID: 30481821]
Exp Eye Res. 2006 Sep;83(3):526-35 [PMID: 16643899]
Cornea. 2005 Jan;24(1):80-5 [PMID: 15604871]
Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2333-6 [PMID: 15223813]
Ocul Surf. 2005 Oct;3(4 Suppl):S154-7 [PMID: 17216108]
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):26 [PMID: 32785678]
Am J Ophthalmol. 2011 Dec;152(6):900-909.e1 [PMID: 22019306]
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):539-49 [PMID: 18234997]
Ocul Surf. 2017 Jul;15(3):438-510 [PMID: 28736340]
Invest Ophthalmol Vis Sci. 2014 Feb 26;55(2):1133-42 [PMID: 24458153]
Arch Ophthalmol. 2009 Dec;127(12):1625-31 [PMID: 20008718]
Recenti Prog Med. 1996 Oct;87(10):508-15 [PMID: 9026858]
Cont Lens Anterior Eye. 2012 Apr;35(2):81-4 [PMID: 21917503]
Adv Exp Med Biol. 1998;438:485-91 [PMID: 9634925]
Arch Immunol Ther Exp (Warsz). 2015 Aug;63(4):299-304 [PMID: 25772203]
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3030-5 [PMID: 15326117]
Am J Ophthalmol. 2000 Jul;130(1):25-32 [PMID: 11004256]
Invest Ophthalmol Vis Sci. 2004 May;45(5):1369-74 [PMID: 15111590]

Grants

  1. P30 CA125123/NCI NIH HHS
  2. P30 EY002520/NEI NIH HHS
  3. P30 EY020799/NEI NIH HHS
  4. R01 EY011915/NEI NIH HHS

MeSH Term

Cornea
Humans
Keratoconjunctivitis Sicca
Osmolar Concentration
Tears